Nazione: Irlanda
Lingua: inglese
Fonte: HPRA (Health Products Regulatory Authority)
Galantamine
PCO Manufacturing Ltd.
N06DA; N06DA04
Galantamine
24 milligram(s)
Prolonged-release capsule, hard
Product subject to prescription which may not be renewed (A)
Anticholinesterases; galantamine
Authorised
2013-05-31
_ _ _ _ PACKAGE LEAFLET: INFORMATION FOR THE USER REMINYL ® XL 8 MG PROLONGED-RELEASE CAPSULES, HARD REMINYL ® XL 16 MG PROLONGED-RELEASE CAPSULES, HARD REMINYL ® XL 24 MG PROLONGED-RELEASE CAPSULES, HARD galantamine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Reminyl XL is and what it is used for 2. What you need to know before you take Reminyl XL 3. How to take Reminyl XL 4. Possible side effects 5. How to store Reminyl XL 6. Contents of the pack and other information 1. WHAT REMINYL XL IS AND WHAT IT IS USED FOR Reminyl XL contains the active substance 'galantamine' an antidementia medicine. It is used in adults to treat the symptoms of mild to moderately severe Alzheimer's disease, a type of dementia that alters brain function. Alzheimer’s disease causes increasing memory loss, confusion and behavioural changes which make it increasingly difficult to carry out normal daily activities. These effects are thought to be caused by a lack of 'acetylcholine', a substance responsible for sending messages between brain cells. Reminyl increases the amount of acetylcholine in the brain and treats the signs of the disease. The capsules are made in a ‘prolonged-release’ form. This means that they release the medicine slowly. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE REMINYL XL DO NOT TAKE REMINYL XL if you are allergic to galantamine or to any of the other ingredients of this medicine (listed in section 6) if you have severe liver or severe kidney disease WARNINGS AND PRECAUT Leggi il documento completo
Health Products Regulatory Authority 16 May 2022 CRN00CY1N Page 1 of 2 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Reminyl XL 24 mg prolonged-release capsules, hard 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 24 mg capsule, contains 24 mg galantamine (as hydrobromide). Excipients with known effect: sucrose For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Prolonged-release capsule, hard _Product imported from Italy and Greece:_ Caramel opaque, size 1 hard capsules with the inscription “G24”, containing white to off-white pellets. 4 CLINICAL PARTICULARS As per PA23211/003/004 5 PHARMACOLOGICAL PROPERTIES As per PA23211/003/004 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS _Prolonged-release pellets_ Diethyl phthalate Ethylcellulose Hypromellose Macrogol 400 Maize starch Sucrose _Capsules_ Gelatin Titanium dioxide (E171) Red ferric oxide (E172) Yellow ferric oxide (E172) _Imprinting ink_ Iron oxide black (E172) Shellac Propylene glycol 6.2 INCOMPATIBILITIES Not applicable. Health Products Regulatory Authority 16 May 2022 CRN00CY1N Page 2 of 2 6.3 SHELF LIFE The shelf life expiry date of this product shall be the date shown on the container and outer packaging of the product on the market in the country of origin 6.4 SPECIAL PRECAUTIONS FOR STORAGE Do not store above 30ºC. 6.5 NATURE AND CONTENTS OF CONTAINER Carton containing 4 blister strips (7 capsules per strip) Pack size: 28 capsules 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING No special requirements. 7 PARALLEL PRODUCT AUTHORISATION HOLDER PCO Manufacturing Ltd. Unit 10, Ashbourne Business Park Rath Ashbourne Co. Meath Ireland 8 PARALLEL PRODUCT AUTHORISATION NUMBER PPA0465/166/003 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 31st May 2013 10 DATE OF REVISION OF THE TEXT May 2022 Leggi il documento completo